This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Pfizer is likely to show GSK significant competition
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
The EU certification will support supplies of drug products registered in Europe, from this manufacturing site
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
Under the terms of the VPPA, IGNIS will produce renewable energy equal to Lonza’s electricity needs across Switzerland and the European Union.
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Subscribe To Our Newsletter & Stay Updated
